Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference
SCOTTSDALE, Ariz., Dec. 07, 2021 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, more...
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease
NEW YORK and SOLANA BEACH, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) — Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from its licensing partner Sentynl Therapeutics, Inc. (“Sentynl”), more...
Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement
Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, Pa. and WALTHAM, Mass. and MUNICH, Germany, Dec. more...
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 13, 2021
HACKENSACK, NJ / ACCESSWIRE / December 6, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), leaders in transformative technology solutions utilized in oncology drug discovery and development will report its financial and operational results for the second more...
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma Topline study results expected in the first half of 2022 Biologics License Application more...
Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration
Input Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant Setting SEATTLE, Dec. 06, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary more...
Oncocyte Corporation Hosting Business Update Call
Tuesday, December 14th @ 2:30pmET IRVINE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that more...
AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors
Robinson’s expertise in development and commercialization adds to the clinical and commercial experience of newly appointed management team GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a more...
Curis Appoints John A. Hohneker, M.D. To Board Of Directors
Curis Appoints John A. Hohneker, M.D. To Board Of Directors PR Newswire LEXINGTON, Mass. , Dec. 6, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for more...
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
– Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 – – Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ more...